Sophiris Bio EBIT

The latest EBIT for SPHS is $-8M as of September 2019. That compares with $-14M in the prior-year period — up 42.2% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Sophiris Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPHS's EBIT moved from $-14M to $-8M — a 42.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sophiris Bio's operating scale or balance-sheet position.

Against Healthcare companies, SPHS currently prints $-8M for EBIT, while the sector average sits near $99B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Sophiris Bio's growth, margins, and balance sheet.

A EBIT figure of $-8M for SPHS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting SPHS's EBIT ($-8M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.